Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Unknown 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Sarcoma, Ewing 2Sarcoma, Clear Cell 2Myoepithelioma 2Liposarcoma, Myxoid 2Histiocytoma, Angiomatoid Fibrous 2Desmoplastic Small Round Cell Tumor 2Chondrosarcoma, Extraskeletal Myxoid 2Sarcoma 1Fibroma 1

Interventions

Doxorubicin 25Radiotherapy 16apatinib 15Cyclophosphamide 15Ifosfamide 13anlotinib 12camrelizumab 10Temozolomide 9Imatinib Mesylate 9Vincristine 8Surgical Procedures, Operative 7Neoadjuvant Therapy 7Methotrexate 7Drug Therapy 7Dactinomycin 5Blood Specimen Collection 5fludarabine phosphate 4Paclitaxel 4Immune Checkpoint Inhibitors 4Etoposide 4Docetaxel 4Carboplatin 4toripalimab 3pembrolizumab 3Trabectedin 3Topotecan 3Surveys and Questionnaires 3Radiation Dose Hypofractionation 3Nivolumab 3Melphalan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × seclidemstat × Sarcoma × Clear all
NCT03600649 2023-11-21

Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas

Salarius Pharmaceuticals, LLC

Phase 1 Unknown
50 enrolled
Sarcoma

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Fibroma, Myoepithelioma, Sarcoma, Sarcoma, Ewing, Liposarcoma, Myxoid, Sarcoma, Clear Cell, Desmoplastic Small Round Cell Tumor

NCT05266196 2023-08-01

A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)

Salarius Pharmaceuticals, LLC

Phase 1/2 Unknown
10 enrolled
Sarcoma

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Myoepithelioma, Sarcoma, Ewing, Liposarcoma, Myxoid, Sarcoma, Clear Cell, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡